MYRIAD GENETICS INC
جودة البيانات: 100%
MYGN
Nasdaq
Manufacturing
Chemicals
KWD 4.35
▼
KWD 0.09
(-2.03%)
القيمة السوقية: 432.01 M
السعر
KWD 4.62
القيمة السوقية
432.01 M
نطاق اليوم
—
نطاق 52 أسبوعًا
—
حجم التداول
—
فتح —
متوسط 50 يوم / 200 يوم
—
متوسط 50 يوم / 200 يوم
—
Quick Summary
النقاط الرئيسية
Revenue grew 4.53% annually over 5 years — modest growth
Debt/Equity of 0.32 — conservative balance sheet
Generating 1.80 M in free cash flow
Revenue growth is decelerating — 1Y growth trails 5Y average by 6.09%
النمو
Revenue Growth (5Y)
4.53%
أعلى من متوسط القطاع (1.82%)
Revenue (1Y)-1.56%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
الجودة
Return on Equity
-96.18%
أقل من متوسط القطاع (-53.34%)
ROIC-57.85%
Net Margin-44.38%
Op. Margin-46.96%
الأمان
Debt / Equity
0.32
أعلى من متوسط القطاع (0.31)
Current Ratio2.33
Interest Coverage-36.88
التقييم
PE (TTM|2027)
-1.18 | 28.50
أعلى من متوسط القطاع (-1.47)
P/B Ratio1.16
EV/EBITDAN/A
Dividend YieldN/A
تاريخ السعر
الاتجاهات المالية
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1364 نظير)
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1364 نظير)| المقياس | السهم | وسيط القطاع |
|---|---|---|
| P/E | -1.2 | -1.5 |
| P/B | 1.2 | 1.6 |
| ROE % | -96.2 | -53.3 |
| Net Margin % | -44.4 | -41.5 |
| Rev Growth 5Y % | 4.5 | 1.8 |
| D/E | 0.3 | 0.3 |
السعر المستهدف للمحللين
10 محللين
Hold
الحالي
KWD 4.35
المستهدف
KWD 7.78
KWD 4.00
KWD 7.00
KWD 18.00
التوقعات
مكرر الربحية المستقبلي
26.84
ربحية السهم المستقبلية
KWD 0.16
نمو ربحية السهم (تقدير)
+242.5%
الإيرادات المقدّرة
915.10 M
تقديرات الأرباح
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| FY2027 |
KWD 0.16
KWD 0.03 – KWD 0.41
|
915.10 M | 12 |
| FY2026 |
KWD 0.05
-KWD 0.06 – KWD 0.22
|
865.81 M | 12 |
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| 2026 Q2 |
KWD 0.01
-KWD 0.03 – KWD 0.05
|
214.67 M | 10 |
| 2026 Q1 |
-KWD 0.07
-KWD 0.09 – -KWD 0.01
|
202.33 M | 11 |
مفاجآت الأرباح
آخر 4 أرباع
| الربع | EPS المقدر | EPS الفعلي | المفاجأة |
|---|---|---|---|
| Q42025 | -KWD 0.02 | KWD 0.04 | +348.3% |
| Q32025 | -KWD 0.01 | KWD 0.00 | +100.0% |
| Q22025 | -KWD 0.01 | KWD 0.05 | +724.2% |
| Q12025 | -KWD 0.05 | -KWD 0.03 | +44.8% |
ETFs Holding This Stock
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -1.56% | Revenue Growth (3Y) | 4.63% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 4.53% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 824.50 M | Net Income (TTM) | -365.90 M |
| ROE | -96.18% | ROA | -52.07% |
| Gross Margin | 69.93% | Operating Margin | -46.96% |
| Net Margin | -44.38% | Free Cash Flow (TTM) | 1.80 M |
| ROIC | -57.85% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0.32 | Current Ratio | 2.33 |
| Interest Coverage | -36.88 | Asset Turnover | 1.17 |
| Working Capital | 196.80 M | Tangible Book Value | 158.10 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -1.18 | Forward P/E | N/A |
| P/B Ratio | 1.16 | P/S Ratio | 0.52 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | 0.42% | ||
| Market Cap | 432.01 M | Enterprise Value | 406.11 M |
| Per Share | |||
| EPS (Diluted TTM) | -3.95 | Revenue / Share | 8.82 |
| FCF / Share | 0.02 | OCF / Share | 0.02 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | -0.49% |
| SBC-Adj. FCF | -43.00 M | Growth Momentum | -6.09 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 824.50 M | 837.60 M | 753.20 M | 678.40 M | 690.60 M |
| Net Income | -365.90 M | -127.30 M | -263.30 M | -112.00 M | -27.20 M |
| EPS (Diluted) | -3.95 | -1.41 | -3.18 | -1.39 | -0.35 |
| Gross Profit | 576.60 M | 585.40 M | — | — | — |
| Operating Income | -387.20 M | -123.50 M | -257.40 M | -140.60 M | -190.50 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 106.80 M | 113.40 M | 88.70 M | 85.40 M | 81.90 M |
| SG&A Expenses | — | — | 572.90 M | 514.70 M | 537.80 M |
| D&A | 53.70 M | 61.20 M | 61.90 M | 52.70 M | 62.80 M |
| Interest Expense | 10.50 M | 2.80 M | 2.90 M | 3.20 M | 6.60 M |
| Income Tax | -29.20 M | 3.80 M | 1.10 M | -28.60 M | -29.90 M |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 706.60 M | 1.03 B | 1.15 B | 1.20 B | 1.32 B |
| Total Liabilities | 338.60 M | 326.50 M | 363.30 M | 312.90 M | 352.90 M |
| Shareholders' Equity | 368.00 M | 701.10 M | 783.20 M | 885.80 M | 967.80 M |
| Total Debt | 119.90 M | 39.60 M | 38.50 M | 0.0 | 0.0 |
| Cash & Equivalents | 149.60 M | 102.40 M | 132.10 M | 56.90 M | 258.40 M |
| Current Assets | 332.60 M | 298.00 M | 313.60 M | 274.60 M | 484.80 M |
| Current Liabilities | 133.80 M | 164.10 M | 155.90 M | 137.20 M | 204.30 M |
{"event":"ticker_viewed","properties":{"ticker":"MYGN","listing_kind":"stock","pathname":"/stocks/mygn","exchange":"Nasdaq","country":"US"}}
